Skip to main content
Premium Trial:

Request an Annual Quote

HemoShear Gets $4.3M SBIR Grant to Develop Predictive Drug Technologies

NEW YORK (GenomeWeb News) – Biotech firm HemoShear today announced a $4.3 million Phase II Small Business Innovation Research grant to profile the effects of 50 known drugs on the human blood vessel system using the company's proprietary human vascular surrogate system.

The grant, the third received by the Charlottesville, Va.-based company in the past two years, is from the National Heart, Lung, and Blood Institute.

HemoShear will use proprietary bioinformatics methods to develop a predictive vascular gene signature that will allow researchers to score new drug compounds for vascular safety risk, the company said, adding that no technologies currently available to drug manufacturers have such capability.

HemoShear develops human and animal cell-based surrogate systems for the discovery and evaluation of new drug compounds, and in a statement, Robert Ruffolo, a member of its scientific advisory board and former president of R&D at Wyeth Pharmaceuticals, said that HemoShear's technology can "play a role in identifying and validating new molecular targets in the vascular system for which new drugs can be designed.

"We now believe the technology will be able to play an important role in predicting both vascular efficacy and side effects of drug candidates earlier in the drug discovery process and thereby reduce the risk of failure in pharmaceutical research and development," he said.

Brett Blackman, co-founder and chief scientific officer of HemoShear, will be the principal investigator on the grant.

The company previously received a Phase I SBIR grant for the development of a human surrogate vascular inflammation system, which has now been validated and is being used in customer research programs, HemoShear said.

In April, it received a Phase I SBIR grant to develop a rodent liver surrogate system as the first step toward developing an advanced human liver system.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.